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Aims Endothelin-1 (ET-1) is a potent vasoconstrictor peptide linked to vascular diseases through a common intronic
gene enhancer [(rs9349379-G allele), chromosome 6 (PHACTR1/EDN1)]. We performed a multimodality investi-
gation into the role of ET-1 and this gene variant in the pathogenesis of coronary microvascular dysfunction
(CMD) in patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease (CAD).
...................................................................................................................................................................................................
Methods
and results
Three hundred and ninety-one patients with angina were enrolled. Of these, 206 (53%) with obstructive CAD
were excluded leaving 185 (47%) eligible. One hundred and nine (72%) of 151 subjects who underwent invasive
testing had objective evidence of CMD (COVADIS criteria). rs9349379-G allele frequency was greater than in con-
temporary reference genome bank control subjects [allele frequency 46% (129/280 alleles) vs. 39% (5551/14380);
P= 0.013]. The G allele was associated with higher plasma serum ET-1 [least squares mean 1.59 pg/mL vs. 1.28 pg/
mL; 95% confidence interval (CI) 0.10–0.53; P= 0.005]. Patients with rs9349379-G allele had over double the odds
of CMD [odds ratio (OR) 2.33, 95% CI 1.10–4.96; P= 0.027]. Multimodality non-invasive testing confirmed the G
allele was associated with linked impairments in myocardial perfusion on stress cardiac magnetic resonance imaging
at 1.5 T (N= 107; GG 56%, AG 43%, AA 31%, P= 0.042) and exercise testing (N= 87; -3.0 units in Duke Exercise
Treadmill Score; -5.8 to -0.1; P= 0.045). Endothelin-1 related vascular mechanisms were assessed ex vivo using wire
myography with endothelin A receptor (ETA) antagonists including zibotentan. Subjects with rs9349379-G allele
had preserved peripheral small vessel reactivity to ET-1 with high affinity of ETA antagonists. Zibotentan reversed
ET-1-induced vasoconstriction independently of G allele status.
...................................................................................................................................................................................................
Conclusion We identify a novel genetic risk locus for CMD. These findings implicate ET-1 dysregulation and support the possi-
bility of precision medicine using genetics to target oral ETA antagonist therapy in patients with microvascular
angina.
...................................................................................................................................................................................................
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registration
ClinicalTrials.gov: NCT03193294.
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Introduction
The coronary microcirculation has been implicated in the patho-
genesis of angina for over 50 years, however, disease mechanisms
remain incompletely understood.1 Coronary microvascular dys-
function (CMD) is associated with adverse outcomes in angina
and a plethora of other cardiovascular disorders.2–5 Standardized
diagnostic criteria for microvascular dysfunction6 underpin recent
studies which have identified the disease prevalence affecting two-
thirds of angina patients without obstructive epicardial coronary
artery disease (CAD).7–10 These patients present a diagnostic and
therapeutic challenge with up to one in four experiencing a major
adverse cardiac event after 5 years of follow-up.11,12 The syn-
drome of ischaemia and no obstructive CAD (INOCA) is particu-
larly important in women,13 whose elevated cardiac risk is mostly
driven by impaired coronary flow reserve (CFR) (and not ob-
structive coronary disease).11
Endothelin-1 (ET-1) is a highly potent endogenous vasoconstrictor
of human coronary arteries14 and has been implicated in the patho-
genesis of microvascular dysfunction.15,16 Endothelin-1-mediated ac-
tivation of the G protein-coupled endothelin A (ETA) receptor on
vascular smooth muscle cells induces endothelial dysfunction, inflam-
mation, and vasoproliferative effects. Circulating concentrations of
serum ET-1 are inversely associated with coronary flow responses in
patients with CMD.14,16 Recently, a common (39%) genetic locus in
chromosome 6p24 (PHACTR1/EDN1) has been shown to be a distal
regulator of endothelin gene expression.17 The allele, rs9349379-G,
is associated with an increased risk for atherosclerotic epicardial
CAD and myocardial infarction.18 This functional single-nucleotide
polymorphism (SNP: rs9349379-G) is associated with increased
endothelin gene expression resulting in a lifetime’s exposure of at
least 20% higher ET-1 precursor levels in the plasma.17 Endothelin-1
dysregulation is implicated in coronary vascular disease, however, the
role of rs9349379 in the pathogenesis of CMD has not been
examined.
We investigated the association, if any, of the rs9349379-G allele
with CMD in angina patients undergoing invasive coronary function
testing. Our secondary objectives were to investigate whether the G
allele associates with non-invasive parameters of myocardial ischae-
mia. Our final objective was to examine vascular mechanisms using
isometric tension recordings in small peripheral resistance vessels
isolated from patients according to genotype. We evaluated ETA re-
ceptor-mediated vasoconstriction in subjects according to
rs9349379-G allele status. These included zibotentan, an ETA
receptor-selective antagonist, which is available for repurposing fol-
lowing neutral results in phase 3 oncology trials.
Methods
Study population
We prospectively enrolled patients with stable angina. We screened
elective adult referrals to two hospitals serving a population of 2.5
million in the West of Scotland. Patients were scheduled to undergo
clinically indicated invasive coronary angiography for the investigation
of suspected CAD. The participants were enrolled into the Coronary
Microvascular Angina (CorMicA) study (ClinicalTrials.gov: NCT03
193294), which was a randomized, controlled, strategy trial of strati-
fied medicine in angina patients without obstructive CAD.19 Rose-
Angina questionnaire was administered on the day of the angiogram
and only patients with definite or possible angina were eligible to par-
ticipate.20 Exclusion criteria included a non-coronary indication for in-
vasive angiography, e.g. valve disease, severe renal dysfunction
(glomerular filtration rate < 30 mL/min), inability to give informed con-
sent and obstructive coronary disease determined during invasive cor-
onary angiography [>_50% diameter stenosis and/or fractional flow
reserve (FFR) <_ 0.80]. All coronary vasodilating drugs were discontin-
ued at least 24 h before the procedure. Pooled control genotype fre-
quencies were ascertained from a contemporary medical genome
reference cohort.21
Definitions: coronary microvascular
dysfunction
We defined CMD using invasive coronary function testing and the
Coronary Vasomotion Disorders International Study Group
(COVADIS) diagnostic criteria.20 These physiological criteria included
an abnormal response to adenosine [raised index of microcirculatory
resistance (IMR) (>_25) and/or abnormal CFR (<2.0)]. In addition,
CMD also included subjects with microvascular spasm during acetyl-
choline (ACh) provocation [reproduction of angina symptoms, ischae-
mic electrocardiogram changes (>_1 mm ST-segment deviation), but
<90% epicardial spasm during ACh testing].22 Coronary microvascular
dysfunction is frequently associated with epicardial vasospasm and
hence patients with abnormal vasoreactivity during adenosine assess-
ment (abnormal IMR and/or CFR) and coexistent epicardial vasospasm
during ACh provocation were included within the CMD group.
Fractional flow reserve was measured to rule-out flow limiting CAD as
an alternative explanation for myocardial ischaemia (INOCA subjects
had an FFR >0.80 in target artery).
2 T.J. Ford et al.
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Measurement of coronary vascular function
in vivo
We used an interventional diagnostic procedure (IDP) that combined
guidewire-based direct measurement of coronary vascular function fol-
lowed by pharmacological vasoreactivity testing. Specifically, the IDP
included a guidewire-based measurement of coronary vascular function
[FFR, CFR and IMR] followed by pharmacological vasoreactivity testing
with ACh and glyceryl trinitrate (GTN) and has been previously
described.19,23
In brief, an intravenous infusion of adenosine (140lg/kg/min) was
administered via a large peripheral vein to induce steady-state maximal
hyperaemia for a period of at least 90 s with a target time of 180 s. A pres-
sure–temperature sensitive guidewire was placed into the distal third of a
major epicardial coronary artery (typically the left anterior descending).
The myocardial FFR was calculated by the ratio of mean distal coronary
pressure to mean aortic pressure during maximal hyperaemia. A FFR
<_0.80 was taken as abnormal and indicative of flow-limiting CAD.24
Coronary flow reserve was calculated using thermodilution as resting
mean transit time divided by hyperaemic mean transit time.25 A CFR <2.0
was defined as abnormal representing impaired vasodilator reserve.26
The IMR was calculated as the product of mean hyperaemic transit time
and mean distal coronary pressure at hyperaemia.27 An IMR >_25 was
defined as abnormal and indicative of increased microcirculatory resist-
ance.28 These invasive parameters were simultaneously derived in real
time using dedicated software (Coroventis, Uppsala, Sweden). We
assessed endothelium-dependent coronary vasomotor function using
intracoronary infusions of ACh via the guiding catheter at concentrations
of 0.182, 1.82, and 18.2mg/mL (10-6, 10-5, and 10-4 mol/L, respectively) at
1 mL/min for 2 min via a mechanical infusion pump.29 Patients who had
CMD (e.g. abnormal CFR and/or IMR) but co-existent epicardial vaso-
spasm during ACh bolus (100lg bolus of ACh; 5.5 mL of 10-4 mol/L over
20 s) were considered in the CMD group.30 In order to assess non-
endothelial dependent vasodilatation, 300mg of GTN was administered
by manual intracoronary bolus injection. Detailed methods are reported
in the Supplementary material online, Appendix.
Blood and tissue analysis
Serum ET-1 was determined using blood obtained on the day of coronary
function testing (Quantikine VR ELISA, R&D SystemsVR Europe, Abington,
UK). Blood was obtained from participants following an overnight fast in
a recumbent position.
Ex vivo pharmacological assessment of peripheral vascular function was
performed on patients who volunteered to undergo a gluteal skin fat bi-
opsy within 4 weeks of the invasive coronary function assessment. The bi-
opsy was obtained under sterile conditions using local anaesthesia with
lidocaine (2%). Small peripheral resistance vessels (<400mm) were care-
fully dissected from fresh biopsies using a light microscope. About 2 mm
length vessels were mounted on 40-lm stainless steel wires for isometric
myography in multi-channel myograph chambers (DMT, Denmark) filled
with physiological saline solution. Isometric tension recordings followed-
on directly using the technique of wire myography to study small periph-
eral resistance arteries with paired cumulative concentration response
curves (CCRCs) to ET-1 in the presence or absence of an ETA receptor
antagonist, either BQ123 or zibotentan (AstraZeneca, UK; Open
Innovation). This vascular biology sub-study was an extension of our
work in INOCA subjects that was previously published in this journal.31
The detailed methods are described in the Supplementary material on-
line, Appendix. The peripheral vascular sensitivity to ET-1 (pEC50) and
maximum vasoconstriction to ET-1 (Emax) were determined.
For the antagonist studies, the affinity (KB) of BQ123 was first deter-
mined in paired vessels from individuals and calculated using Schild
regression. The pKB (-log10 KB) values were compared between each
genotype as an indicator of whether or not patients of different geno-
types are likely to respond equally well to an ETA antagonist used clinical-
ly. A final series of experiments involved paired vessel experiments using
ET-1 CCRCs in the presence and absence of a highly selective ETA recep-
tor antagonist, zibotentan to determine a pKB value and assess whether
zibotentan could reverse an established ET-1-mediated vessel
constriction.
Cardiac magnetic resonance imaging and
ischaemia testing protocol
Patients were prospectively invited to undergo quantitative perfusion car-
diac magnetic resonance (CMR) imaging at 1.5 T using pharmacological
stress testing with intravenous adenosine (140mg/kg/min) within 6 weeks
of the index coronary angiogram. CMR studies were performed using a
standardized CMR protocol (Siemens MAGNETOM Avanto, Erlangen,
Germany). The CMR scans were interpreted by two experienced
observers (D.C., C.B.) with Level III accreditation of the European
Association of Cardiovascular Imaging (EACVI), blind to diagnostic find-
ings and genotype. The raw stress and rest perfusion images were qualita-
tively assessed for inducible or fixed perfusion defects. The perfusion was
classified as either normal, abnormal, or equivocal. If a perfusion defect
was present, it was reported as having an epicardial, microvascular or
equivocal pattern. Perfusion defects were then reported on a segmental
basis according to the American Heart Association 16-segment model32
and were classified according to the transmurality of the perfusion defect
(<50% or >50%), and the number of segments with qualitatively abnor-
mal perfusion was defined. Dark rim artefact was adjudicated based on
standardized criteria.33
The first-pass perfusion images were then post-processed to derive
quantitative pixel perfusion maps to derive absolute myocardial blood
flow and myocardial perfusion reserve (MPR) (further detail in
Supplementary material online).34
Treadmill exercise stress electrocardiography using the Bruce proto-
col was analysed from the subgroup of patients who had been pre-
selected for this procedure on clinical grounds prior to invasive coronary
angiography. We used the Duke treadmill score (DTS) which is a vali-
dated metric with established prognostic cardiovascular utility.35 The ex-
ercise treadmill test analysis included (i) exercise duration and (ii) the
DTS36 by a cardiology researcher (EY) blinded to genotype and invasive
physiology. The DTS is based on the occurrence of angina during tread-
mill exercise testing, ST-segment depression during the test and peak ex-
ercise duration (or metabolic equivalent of task achieved). Specifically,
the DTS equals the maximum exercise time in minutes - (5 the max-
imal net ST-segment deviation in mm during or after exercise) - (4 the
treadmill angina index (where 0 = no angina, 1 = non-limiting angina,
2 = exercise limiting angina).
All subjects were asked to abstain from caffeine-containing beverages
or foodstuffs for 24 h, and vasoactive medications for 48 h prior to the
CMR examination. All scan acquisitions were spatially co-registered. All
CMR analyses were performed by a blinded analyst with Level 3 EACVI
accreditation.
Statistical analysis
The main hypothesis in our study was that regulation of ET-1 gene ex-
pression reflected by the presence of the intronic ET-1 gene enhancer,
rs9349379-G, associates with invasive tests of CMD. We tested the asso-
ciation of genotype (SNP rs9349379 G-A allele status) with CMD on in-
vasive coronary vasoreactivity testing by calculating the odds ratio (OR)
and its 95% confidence intervals (CIs). Multivariable logistic regression
was used to determine whether genotype was independently associated
Genetic dysregulation of ET-1 and microvascular dysfunction 3
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with CMD (as defined by abnormal response to intracoronary ACh and/
or systemic adenosine) adjusting for overall cardiac risk (ASSIGN score)
including previous cardiac events.37
Categorical data are presented as percentages and continuous param-
eters are shown as means with standard deviation values or medians with
interquartile ranges. For secondary analyses, subjects were divided into
three genotype groups. Kruskal–Wallis test was used to test whether dis-
tribution of non-parametric variables is the same between the groups.
Subgroup analysis of A vs. G genotypes was determined a priori to evalu-
ate any differences between the two most differentiated groups. The least
squares (LS) mean of serum ET-1 levels was compared between the
groups derived using analysis of co-variance with serum ET-1 as depend-
ent variable and adjusted for age, sex, body mass index, genotype and car-
diovascular risk as covariates and possible confounders. Linear
associations with invasive and non-invasive metrics of microvascular dis-
ease were performed by analysis of variance (ANOVA) with P for linear
trend for continuous parameters and v2 test with P for linear-by-linear
test for categorical variables. Statistical analyses were performed with
Prism 7.0 (GraphPad, La Jolla, CA, USA) and SPSS 25.0 (SPSS, Chicago, IL,
USA).
Results
We prospectively enrolled 391 patients with angina between 25
November 2016 and 11 December 2017 at two hospitals serving a
population of 2.5 million in the West of Scotland (CorMicA:
ClinicalTrials.gov NCT03193294).19 Invasive coronary angiography
revealed obstructive disease in 206 (53.7%) participants who were
then excluded from further study. One hundred and fifty-one partici-
pants with no obstructive coronary disease continued in the study
(Take home figure, Table 1). Evidence of CMD was found in 109 (72%)
of 151 subjects undergoing invasive coronary vasoreactivity testing
(Table 2). An overview of the study and investigations is illustrated in
Take home figure. Genetic analysis was completed in 140 subjects
(93%) using baseline venous blood samples. The mean age of patients
in this analysis 61.1± 10.1 years. There was a predominance of
women [103 (74%)] and the estimated 10-year risk of cardiovascular
events (ASSIGN) was appreciable at 25% (±20).
The genotype distribution of rs9349379 was AA (N= 50, 36%),
AG (N= 51, 36%), and GG (N= 39, 28%). This SNP did not fulfil
Hardy Weinberg equilibrium (P= 0.0015) reflecting biologic ascer-
tainment of genotypes. One hundred and forty subjects underwent
genetic analysis for (rs9349379-G allele) with an allele frequency of
46% (129/280 alleles). The allele frequency was increased in our an-
gina cohort compared to that of genome bank control subjects
[rs9349379-G allele frequency 39% (5551/14380); v2 = 6.15,
P= 0.013].21 The rs9349379-G allele was associated with over dou-
ble the odds of CMD (OR 2.33, 95% CI 1.10–4.96; P= 0.027;
Figure 1A). Subjects with G allele had higher circulating serum ET-1
concentration (LS mean 1.59 pg/mL vs. 1.28 pg/mL; difference
0.31 pg/mL; 0.10–0.52; P= 0.005; Figure 1B). Each additional G allele
Take home figure Study overview: endothelin-1 gene enhancer in microvascular angina. Three hundred and ninety-one patients with stable an-
gina were prospectively enrolled without prior knowledge of coronary anatomy. One hundred and eighty-five (47%) had no obstructive coronary ar-
tery disease and thus eligible for invasive coronary vasoreactivity testing and further sub-studies. One hundred and fifty-one of 185 (82%) were able
to undergo adjunctive invasive tests for coronary microvascular dysfunction. One hundred and nine (72%) subjects tested had evidence of coronary
microvascular dysfunction. One hundred and forty subjects underwent genetic analysis for rs9349379-G allele with an allele frequency of 46% (129/
280 alleles). The frequency of detrimental G alleles was higher than reference genome bank control subjects (46% vs. 39%; P= 0.013). Patients with
rs9349379-G allele had higher serum endothelin-1 and over double the odds of coronary microvascular dysfunction (odds ratio 2.33, 95% confidence
interval 1.10–4.96; P= 0.027). In addition, subjects were more likely to have impaired myocardial perfusion (P= 0.04) and exercise tolerance (-3.0
units in Duke Exercise Treadmill Score; P= 0.045). Peripheral small artery reactivity to endothelin-1 and affinity of ETA receptor antagonists were
preserved in the rs9349379-G allele group (P= 0.209). Crucially, zibotentan tested at clinically relevant concentrations, fully reversed an established
endothelin-1 vasoconstriction, indicative of efficacy in conditions associated with vasospasm. This suggests that ETA receptor antagonism in this group
of patients may have therapeutic benefit.
4 T.J. Ford et al.
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..was linearly associated with CMD on invasive interrogation (Figure
2A; P= 0.021). On multivariable analysis, the G allele remained associ-
ated with CMD (OR per G allele 2.31; 1.08–4.91; P= 0.030;
Supplementary material online, Table S1).
Considering diagnostic subtypes of microvascular dysfunction, the
vast majority had CMD during adenosine interrogation (73% abnor-
mal CFR and/or IMR) and only 27% of the genotyped population had
isolated microvascular spasm (isolated CMD to ACh only). There
was a statistically significant relationship between genotype and
CMD, as reflected by an impaired coronary vasodilator reserve (ab-
normal CFR: AA 20%, AG 35%, and GG 41%;Figure 2B; P= 0.030).
A similar relationship was noted for prevalence of abnormal micro-
vascular resistance in each genotype (abnormal IMR: AA 24%, AG
33%, and GG 46%; Figure 2C; P= 0.029). Coronary flow reserve
decreased linearly with each additional rs9349379-G allele [AA 3.0
(2.1–3.7); AG 2.7 (1.8–3.5); GG 2.1 (1.7–3.2); overall P= 0.046; Figure
2D; Table 2]. The highest risk group (GG) had a significantly lower
CFR than the AA group (median difference 0.84, 95% CI 0.1–1.1).
The prevalence of abnormal invasive ACh response was not statistic-
ally different between the groups (any G allele 36% vs. no G allele
30%, P= 0.463). Patients with isolated CMD to ACh (microvascular
spasm) had similar ET-1 levels to those without (1.33 ng/mL vs.
1.28 ng/mL; P= 0.769). The highest serum ET-1 levels were seen in
subjects with concordant abnormalities in both CFR and IMR with lin-
ear stepwise reduction compared to those with only one index of
CMD and lowest in those without any abnormalities [mean 1.67 ng/
mL (both) vs. 1.39 ng/mL (one) vs. 1.31 ng/mL (none); P trend =
0.041].
The Gensini angiographic score reflecting the extent (or burden)
of coronary atherosclerosis was higher in the rs9349379-GG group
[median score 1.0 (0.0–6.0)] compared to the AA group [median
score 0.0 (0.0–2.0); P= 0.037; Table 2]. As might be expected in this
population of INOCA patients, the physiological burden of epicardial
CAD was similar between the groups [myocardial FFR, AA 0.88
(±0.05); AG 0.88 (0.06); GG 0.88 (±0.05); P= 0.977].
One hundred and seven subjects underwent an adenosine stress
perfusion cardiac magnetic resonance imaging (MRI) within 6 weeks
of the invasive angiogram. Forty-six (43%) patients had evidence of a
sub-endocardial circumferential abnormality of myocardial perfusion
attributable to CMD (Table 2). The rs9349379-G allele was associ-
ated with abnormal myocardial perfusion disclosed by stress perfu-
sion MRI (AA 31%, AG 43%, GG 56%; P= 0.042, Figure 3A). The
.................................................................................................
....................................................................................................................................................................................................................
Table 1 Baseline demographics by genotype
SNP (rs9349379) genotype (n5 140) P-valuea
AA (N550) AG (N5 51) GG (N539)
Clinical features
Age (years) 60.6 (±11) 61.1 (±10) 61.6 (±10) 0.649
Female 36 (72%) 36 (71%) 31 (80%) 0.607
ASSIGN scoreb 24 (±21) 27 (±23) 25 (±19) 0.811
Dyslipidaemia 12 (24%) 10 (20%) 8 (21%) 0.671
Hypertension 30 (60%) 32 (63%) 27 (69%) 0.382
Previous cardiovascular eventc 10 (20%) 10 (20%) 13 (33%) 0.239
Diabetic 9 (18%) 11 (22%) 6 (15%) 0.794
Smoker 6 (12%) 8 (16%) 9 (23%) 0.169
Family history 17 (34%) 13 (26%) 13 (33%) 0.886
Peripheral vascular disease 2 (4%) 3 (6%) 2 (5%) 0.789
Atrial fibrillation 5 (10%) 4 (8%) 1 (3%) 0.195
Pulse (rate/min) 69 (±11) 67 (±11) 71 (±11) 0.697
Systolic blood pressure (mmHg) 138 (±22) 136 (±31) 138 (±25) 0.951
Diastolic blood pressure (mmHg) 73 (±11) 74 (±15) 70 (±12) 0.260
Body mass index (kg/m2) 30.4 (±8) 30.4 (±6) 29.4 (±7) 0.515
Laboratory investigations
Cholesterol (mmol/L) 3.5 (±1) 3.5 (±1) 3.6 (±1) 0.904
Glucose (mmol/L) 4.6 (±1) 5.0 (±2) 4.7 (±2) 0.774
C-reactive protein (mg/L) 3.2 (±5) 3.2 (±5) 3.1 (±4) 0.920
N-terminal brain natriuretic peptide (pg/mL) 140 (±187) 157 (±197) 135 (±153) 0.937
Endothelin-1 (pg/mL)d 1.27 (0.42) 1.41 (0.63) 1.46 (0.56) 0.097
Data are expressed as mean (standard deviation) or number (%).
ACE-I, angiotensin converting enzyme inhibitor; ACh, acetylcholine; BMI, body mass index; CCB, calcium channel blocker; CFR, coronary flow reserve; FFR, fractional flow re-
serve; IMR, index of microcirculatory resistance; LVEDP, left ventricular end-diastolic pressure; MI, myocardial infarction.
aP-value represents between group ANOVA for linear trend (continuous data) or Pearson v2 test for linear trend (categorical data) or Kruskal–Wallis testing probability that
the distribution of non-parametric variables are the same across the groups.
bASSIGN risk—predicted 10-year risk of cardiovascular event.
cPrevious myocardial infarction or cerebrovascular event (including transient ischaemic attack).
dEndothelin-1 levels were available in 137 genotyped subjects with significance determined using one-way ANOVA (linear trend).
Genetic dysregulation of ET-1 and microvascular dysfunction 5
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/doi/10.1093/eurheartj/ehz915/5714931 by guest on 27 July 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..association of genotype with CMD was more robust when consider-
ing subjects with either a circumferential subendocardial perfusion
defect disclosed by MRI or invasive evidence of CMD (AA 65%, AG
85%, GG 91%; P< 0.001; Figure 3B). The absolute global and suben-
docardial perfusion reserve (MPR) was numerically lower with each
G allele; however, the differences were not statistically significant
(Table 2; Figure 3C and D).
We then assessed relationships between exercise treadmill testing,
invasive measures of coronary vascular function and genotype.
Ninety subjects prospectively completed exercise treadmill testing
during standard care diagnostic work up prior to invasive coronary
angiography, 84 of these subjects were included in the study with the
remainder being excluded due to lack of genotype or exercise data.
The mean exercise duration was 367 s (±156 s) and similar between
the groups (Table 2). The mean DTS was -1.0 (±5.3) units. The
presence of CMD was associated with reduced DTS (CMD -2.3 vs.
no CMD þ3.5; difference -5.8 units, 95% CI -8.2 to -3.3; P< 0.001;
Figure 3E). Overall, there was a moderate inverse correlation be-
tween presence of CMD and the DTS (Spearman’s rho = -0.42;
P< 0.001). Considering the cohort of 84 patients in whom genotype
and DTS were both available, there was a lower DTS for each add-
itional G allele consistent with increasing ischaemia with ET-1 gene
enhancement. A priori analysis of high-risk subjects (homozygous for
the minor G allele) compared to the AA group revealed a mean dif-
ference of -3.0 units in DTS (95% CI -5.8 to -0.1; P= 0.045)
(Figure 3F). There was a modest correlation between the continuous
DTS and genotype (Spearman’s rho -0.21; P= 0.055), that was not
statistically significant. The angina index during exercise was linearly
associated with G allele status (non-limiting or limiting angina AA
59% vs. AG 68% vs. GG 87%; P trend =0.036). The exercise time was
............................................................................................
....................................................................................................................................................................................................................
Table 2 Invasive coronary physiology and non-invasive stress testing
SNP (rs9349379) genotype P-valuea
AA (N5 50) AG (N5 51) GG (N539)
Minor non-obstructive CADb 25 (50%) 30 (59%) 24 (62%) 0.265
Coronary atheroma burden (Gensini score)c 0 (0.2) 2 (0.5) 1 (0.6) 0.037
Left ventricular end-diastolic pressure (mmHg) 10 (±4) 10 (±5) 9 (±3) 0.520
Fractional flow reserve (FFR) 0.88 (0.05) 0.88 (0.06) 0.88 (0.05) 0.977
Coronary microvascular dysfunction (any) 30 (60%) 38 (75%) 32 (82%) 0.021
Abnormal CFR (<2.0) 10 (20%) 18 (36%) 16 (41%) 0.030
Coronary flow reserve (CFR) 3.0 (2.1–3.7) 2.7 (1.8–3.5) 2.1 (1.7–3.2) 0.046
Abnormal IMR (>_25) 12 (24%) 17 (33%) 18 (46%) 0.029
Microcirculatory resistance (IMR) 18.9 (15.2–24.2) 18.6 (14.2–29.3) 22.1 (13.8–29.3) 0.879
Abnormal CFR or IMR 20 (40%) 26 (51%) 27 (69%) 0.007
Microvascular spasm (during acetylcholine) 15 (30%) 21 (42%) 12 (31%) 0.385
Exercise treadmill testing (N = 87) 28 (56%) 34 (67%) 25 (64%)
Duration (s) 393 (±124) 352 (±157) 384 (±162) 0.827
METs 7.8 (±2.1) 7.4 (±2.6) 7.6 (±2.1) 0.786
Angina on treadmill 16 (59%) 23 (68%) 20 (87%) 0.036
Peak systolic blood pressure (mmHg) 178 (±30) 173 (±34) 182 (±25) 0.688
Duke Treadmill Score -0.3 (±6.0) -0.6 (±4.7) -3.3 (±4.2) 0.045
Stress perfusion magnetic resonance imaging (N = 107)
Inducible myocardial perfusion defect 11 (31%) 17 (43%) 18 (56%) 0.042
Inducible myocardial perfusion defect with CMD 4 (13%) 14 (37%) 15 (47%) 0.016
Myocardial perfusion reserve (global) 1.8 (±0.4) 1.7 (±0.4) 1.6 (±0.4) 0.154
Myocardial perfusion reserve (endocardium) 1.7 (±0.4) 1.6 (±0.4) 1.5 (±0.4) 0.162
Left ventricular end diastolic volume (indexed, mL/m2) 68.5 (±13.6) 70.1 (±13.2) 70.2 (±11.9) 0.591
Left ventricular end systolic volume (indexed, mL/m2) 23.4 (±6.0) 25.4 (±8.8) 23.1 (±5.8) 0.848
Left ventricular ejection fraction (%) 65.9 (±4.4) 64.5 (±6.5) 67.3 (±5.2) 0.321
Stroke volume (indexed, mL/m2) 45.0 (±8.8) 44.7 (±7.0) 47.1 (±8.2) 0.298
Left ventricular mass (indexed, mL/m2) 42.0 (±7.0) 42.3 (±8.1) 42.1 (±7.8) 0.924
Data are expressed as mean (±SD), median (IQR), or N (%).
CAD, coronary artery disease; CFR, coronary flow reserve; FFR, fractional flow reserve; LVEDP, left ventricular end-diastolic pressure; IMR, index of microcirculatory resist-
ance; METS, metabolic equivalent of task.
aP-value represents between group ANOVA for linear trend (continuous data) or Pearson v2 test for linear trend (categorical data), Kruskal–Wallis test of probability that the
distribution of non-parametric variables are the same across the groups.
bCore-laboratory adjudication of any angiographic evidence of coronary atherosclerosis including any minimal angiographic luminal irregularity.
cGensini angiographic score is a metric of angiographic disease severity incorporating lesion severity and location. Detailed MRI methodology available in Supplementary mater-
ial online, Appendix.
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Figure 1 Detrimental effects of rs9349379-G allele on coronary microvascular function and endothelin-1. (A) Patients with G allele were over
twice as likely to have underlying microvascular dysfunction (odds ratio per G allele 2.33, 95% confidence interval 1.10–4.96; P= 0.027) Even after ad-
justment for other risk factors the G allele was predictive of microvascular disease (odds ratio 2.31; 95% confidence interval 1.0–4.91). This finding
supports a detrimental impact on the coronary microcirculation of a lifetime of increased endothelin gene expression. (B) In a multivariable regres-
sion model adjusting for baseline group differences, patients with rs9349379-G allele had higher plasma endothelin-1 (least squares mean 1.59 pg/mL
vs. 1.28 pg/mL; 95% confidence interval 0.10–0.53; P= 0.005).
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Figure 2 Genotype: phenotype association of G allele with invasive coronary microvascular dysfunction. (A–C) The prevalence of microvascular
dysfunction detected during invasive coronary testing was associated with genotype status (AA 60%, AG 75%, GG 83%; P= 0.021). Presence of ab-
normal coronary flow reserve and microcirculatory resistance were linearly associated with each additional G allele. P-value represents Pearson v2
test for linear trend (categorical data). (D) Coronary flow reserve was lower amongst subjects with two high-risk G alleles (rs9349379) consistent
with detrimental effects of increased endothelin gene expression on the coronary microcirculation (Kruskal–Wallis between groups dotted line,
P= 0.046). A priori subgroup analysis (AA vs. GG group—solid line) showed lower CFR in the GG group (P= 0.013). Data are median CFR plus
error bars represent 95% confidence intervals for the median. P= 0.021, P= 0.030, P= 0.029 and P= 0.046.
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..not significantly lower amongst subjects with the G allele (365 vs.
392 s; P= 0.423).
Sixty-eight genotyped subjects agreed to participate in a vascular
biology sub-study, providing written informed consent for a gluteal
subcutaneous biopsy within 4 weeks of coronary angiography.
Subjects who volunteered to have a biopsy were of similar age and
cardiac risk to those who declined to participate in the sub-study [bi-
opsy participants mean age 62± 9 years vs. 61± 11 years (P= 0.134),
ASSIGN score 23% ± 18 vs. 28% ± 23 (P= 0.198)]. Forty-four (65%)
of these patients had biopsies with a sufficient number of small
arteries to undergo paired CCRCs to ET-1 in the presence and ab-
sence of an ETA receptor antagonist, either BQ123 or zibotentan
(ZD4054; AstraZeneca, Cambridge, UK). Grouping according to
genotype (AA, n= 16; AG, n= 14; GG, n= 14) and vasodilator
responses to ACh (ACh Emax) were similar (Table 3). Similarly, ves-
sels had similar potency for ET-1 (pEC50 AA 9.34, AG 9.45, and GG
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Figure 3 Genotype: phenotype association of G allele with non-invasive ischaemia testing. (A) Cardiovascular stress magnetic resonance imaging
at 1.5 T (N= 107). There was a linear relationship between the G allele and presence of an inducible perfusion defect on cardiac magnetic resonance
(v2 test for linear trend P= 0.042). (B) The relationship was more robust when considering with invasive evidence of coronary microvascular dysfunc-
tion and/or inducible perfusion defect. Over 90% of GG subjects had at least one abnormality compared with only 65% of AA subjects (P< 0.001). (C
and D) Myocardial perfusion reserve was numerically reduced in AG and GG subjects compared with AA subjects; however, this was not statistically
significant (P-value represents analysis of variance test for trend). Error bars represent 95% confidence intervals for the mean. (E) Invasive evidence of
microvascular dysfunction (defined by abnormal response to intracoronary acetylcholine and/or systemic adenosine) was functionally significant and
associated with ischaemic burden on symptom limited exercise treadmill testing (coronary microvascular dysfunction -2.3 vs. no coronary micro-
vascular dysfunctionþ3.5; difference -5.8 units; -8.2 to -3.3; P< 0.001). (F) Exercise treadmill testing (n= 84). There was a relationship between geno-
type group and worsening ischaemia on stress testing (analysis of variance P-trend = 0.045). The mean difference in ischaemia by Duke treadmill
score between group GG and group AA was -3.0 units (95% confidence interval -5.8 to -0.1; P= 0.045). Error bars represent 95% confidence inter-
vals for the mean.
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9.32; P= 0.533) and maximum vasoconstriction to ET-1 (Emax AA
122.3%, AG 115.5%, GG 129.7%; P= 0.533; Figure 4A; Table 3).
Notably, the selective ETA receptor antagonist, BQ123, caused a
parallel rightward shift of the CCRC with comparable pKB values be-
tween groups AA, AG, and GG [pKB values of 7.07 (±0.23), 7.79
(±0.35), and 7.41 (±0.26), respectively; P= 0.209; Figure 4B].
Zibotentan, a highly selective orally active ETA receptor antagonist,
attenuated the constrictor response to ET-1 with pKB of 7.54 (95%
CI 7.27–7.82), comparable to that of BQ123, pKB 7.53 (95% CI 7.37–
7.69).
Crucially, these studies confirmed that zibotentan produced a
concentration-dependent inhibition of an established constrictor re-
sponse to ET-1 and was still efficacious in subjects with G allele
(P< 0.001; Figure 4C). Figure 5 shows representative investigations
from a female subject with few traditional cardiovascular risk factors
but high-risk ET-1 enhancer genotype (GG).
Discussion
We identify a novel genetic risk locus for CMD. Our study extends a
report from the WISE investigators on genotype associations with ar-
terial vasomotion.13 Our results support the hypothesis that dysregu-
lation of the ET-1/ETA receptor system underpins abnormalities in
the coronary microcirculation leading to myocardial ischaemia.
Firstly, rs9349379-G allele status is associated with higher serum ET-
1 and the presence and extent of CMD in patients with angina but
without obstructive coronary disease. Secondly, the genetic poly-
morphism associates with ischaemia testing using distinct, non-
invasive modalities including exercise stress electrocardiography and
stress perfusion CMR. Thirdly, we demonstrate in ex vivo human small
peripheral resistance vessels that the ETA vasoconstrictor response
is not down-regulated in the presence of increases in endothelin
gene expression and ET-1 activity in patients with the rs9349379-G
allele. Finally, we provide proof-of-concept mechanistic data support-
ing a role for zibotentan, an orally active highly selective ETA receptor
antagonist, in reversing established ET-1-mediated vasoconstriction.
These findings have potential clinical relevance since zibotentan is
available for repositioning as a novel, disease-modifying therapy in
this patient population. The results of our study support the rationale
for the ‘Precision Medicine with Zibotentan in Microvascular Angina
(PRIZE)’ trial involving gene testing for the SNP rs9349379 and linked
therapy (ClinicalTrials.gov Identifier: NCT04097314).
Endothelin dysregulation
Pre-clinical studies in experimental models of CMD implicate
increased cardiac ET-1 production leading to endothelial dysfunction,
enhanced vascular expression of rho-kinases, and reactive oxidant
species such as superoxide and enhanced ET-1-mediated vasocon-
striction.38 In patients with angina but no obstructive CAD, micro-
vascular dysfunction is a systemic phenomenon characterized by
peripheral endothelial dysfunction and enhanced peripheral small-
vessel vasoconstriction.31,39 Further, impaired coronary microvascu-
lar function and the propensity to myocardial ischaemia may increase
longer-term risk of major adverse cardiac events.40,41 Our study is
distinct and builds on our prior vascular studies of ET-1 in micro-
vascular angina as we used zibotentan which has more potential for
clinical translation requiring future phase II studies.31 In addition, sub-
jects were analysed by ET-1 rs9349379-G allele status rather than
presence or absence of CMD. We observed that chronic exposure
to increased circulating concentrations of ET-1, as reflected by
rs9349379-G allele status, did not lead to down-regulation to ETA-
mediated ET-1 vasoconstriction in patients with microvascular an-
gina. The converse SNP (rs9349379-A) was recently found to be
associated with spontaneous coronary artery dissection (SCAD)
which typically occurs in patients without atherosclerosis.21 This find-
ing is consistent with our work, particularly given that microvascular
function is typically normal in SCAD.42
We showed that rs9349379-G allele was associated with higher
serum ET-1 levels which is consistent with previous studies whereby
the SNP associates with higher levels of ET-1 and its precursor (Big
ET-1) in healthy subjects. Interestingly, the ET-1 plasma concentra-
tion in our INOCA population is comparable to ET-1 plasma concen-
trations in other conditions including pulmonary artery
............................................................................................................................
....................................................................................................................................................................................................................
Table 3 Pathophysiology: vascular biology of ET-1
SNP (rs9349379) genotype (n5 44) P-valuea
AA (N5 16) AG (N5 14) GG (N5 14)
Vessel diameter (um) 344 (±88) 342 (±89) 347 (±125) 0.851
Vessel length (mm) 1.85 (±0.12) 1.87 (±0.10) 1.82 (±0.11) 0.276
ACh Emax (%) 77.7 (52.9–97.8) 80.2 (59.9–97.6) 92.5 (57.8–99.1) 0.696
ACh pEC50 7.28 (6.88–7.82) 7.26 (6.82–8.00) 6.96 (6.84–7.44) 0.308
ET-1 Emax (%) 122.3 (115.7–134.7) 115.5 (107.5–125.2) 129.7 (115.8–151.2) 0.533
ET-1 pEC50 9.34 (9.15–9.52) 9.45 (9.24–9.67) 9.32 (8.96–9.69) 0.533
BQ123 pKB (±SEM) 7.07 (±0.23) 7.79 (±0.35) 7.41 (±0.26) 0.209
Forty-four (65%) of 68 patients who underwent invasive biopsies had a sufficient number of small arteries to undergo paired cumulative concentration response curves
(CCRCs) to ET-1 in the presence and absence of an ETA receptor antagonist. Data are expressed as mean (±SD) or mean (95% CI for pooled best fit CCRC). CCRC, cumula-
tive concentration response curves were drawn with best-fit derived values. pKB data involved paired vessels undergoing ET-1 CCRC in the presence or absence of BQ123
ETA receptor antagonist (available in 37 out of the 44 subjects: AA N= 14; AG N= 10; GG N= 13).
aSignificance determined using ANOVA for normally distributed means, Kruskal–Wallis test used for between group comparison of non-parametric variables and extra-sum of
squares F test (for CCRC pooled best fit ET-1 data). There were no differences in between group baseline demographics in this vascular sub-study.
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..hypertension43 but lower than in other INOCA cohorts.44 We ac-
knowledge that abluminal secretion of ET-1 away from endothelial
cells towards underlying vascular smooth muscle means circulating
concentrations of ET-1 are an imperfect measure of ET-1 activity in
vascular tissues.45 Chronic elevation of circulating ET-1 may lead to
adaptive down-regulation of its endogenous G-protein coupled
receptors. This phenomenon has been described for ETA receptors
in mice in which the clearing ETB receptor has been knocked out.
46
Cardiovascular risk factors, including blood pressure, were not asso-
ciated with rs9349379-G allele in our population, whereas an inverse
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Figure 4 Endothelin-1 ex vivo vascular biology by genotype. (A) cumulative concentration response curve to endothelin-1 in the three groups in
the presence and absence of ETA antagonist BQ123 (n= 44). Similar antagonist potency (rightward curve shift) for each group suggesting firstly that
the ETA receptors are the dominant effectors of the endothelin-1 vasoconstrictor response and secondly that the ETA receptor pathway is not
down-regulated in spite of the elevated endothelin-1 gene expression and known increase in endothelin-1 activity in the G allele single-nucleotide
polymorphism patients. (B) Antagonist potency of novel therapeutic oral ETA receptor antagonist zibotentan [N= 8, mean 7.54 (95% confidence
interval 7.27–7.82)] is similar to peptide antagonist BQ123 [N= 27, mean 7.53 (95% confidence interval 7.37–7.69)]. Higher pKB represents a higher
antagonist potency. (C) Zibotentan: reversal of established endothelin-1 vasoconstriction. Proof of concept dose-dependent reversal of potent and
established endothelin-1-mediated peripheral arteriolar vasoconstriction. Crucially, the highest concentration tested which is also the plasma con-
centration achieved by a clinically relevant dose of 10 mg/day rapidly and fully reversed the established endothelin-1 constrictor response, indicative
of efficacy in conditions of vasospasm. Comparison using ordinary two-way analysis of variance including time and dose both significant factors
(P< 0.001 after adjustment for multiple testing).
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Figure 5 GG (high-risk endothelin-1 gene enhancer). Illustrative case from a patient with stable angina including representative images from inva-
sive and non-invasive work up are shown in relation to clinical presentation and endothelin-1 enhancer genotype. Maximum ST represents the max-
imum planar or down sloping ST-segment depression during the exercise treadmill test. Invasive coronary angiography of both subjects is near
identical showing only minimal luminal irregularities. White arrows represent subendocardial inducible ischaemic myocardium during adenosine
stress magnetic resonance imaging in a patient with severe coronary microvascular dysfunction. Ex vivo vascular biology (bottom panel) shows typical
endothelin-1-mediated vessel constriction during wire myography. Increasing vessel tension corresponds to the rising curve at each dose titration. A
paired identical vessel experiment is performed after incubation with BQ123, an ETA receptor antagonist. This curve is marked in blue, the curve of
endothelin-1 response is shifted to the right indicating that the ETA receptor mediates vasoconstriction. Despite the endothelin-1 gene enhancer, the
GG subject does not appear to have ETA receptor down-regulation with similar levels of antagonist potency. This supports that ETA receptor antag-
onism in this group of patients may have therapeutic benefit. CFR, coronary flow reserve; ETA, endothelin A receptor; FFR, fractional flow reserve;
IMR, index of microcirculatory resistance.
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associations have been observed in much larger populations.17 This is
particularly interesting given its association with atherogenesis and
CAD. It is thought that excess ET-1 effects healthy populations medi-
ate hypotension via hypotension via ETB-induced nitric oxide and
prostacyclin production, resultant vasodilation, diuresis, and natri-
uresis.47 Our study was underpowered to determine significant dif-
ferences between baseline blood pressures which may also be
confounded by treatment for hypertension.
Microvascular angina is a chronic, debilitating condition of unmet
therapeutic need. Our vascular pharmacology findings indicate that
despite a genetic predisposition to enhanced endothelin gene expres-
sion based on the rs9349379-G allele status, potentially leading to
lifelong enhanced exposure to circulating concentrations of ET-1, the
net effect on ET-1 response or sensitivity to ETA antagonists was
similar between the groups by rs9349379 allele status. The ETA re-
ceptor may not be down-regulated in affected patients raising the po-
tential for health gain by treatment with a selective ETA receptor
antagonist, such as zibotentan. Importantly, BQ123 fully blocked the
constrictor responses in all of the groups. Our vascular pharmacol-
ogy study was specifically focused on the relationships between the
rs9349379-G allele status, ET-1 vasoactive responses, and ETA recep-
tor blockade. Patients with microvascular angina may have similar tis-
sue responses to oral ETA receptor blocker therapy—this important
possibility merits further (NCT04097314).
In a mechanistic, randomized, controlled trial in patients with
microvascular angina, Johnson and Gould48 reported that ETA recep-
tor antagonism increased (improved) the homogeneity of resting
myocardial perfusion. Their study used cardiac positron emission
tomography (PET) to quantify the homogeneity index (a visual notion
of homogeneity derived from PET).49 Kaski et al.50 showed that
patients with microvascular angina were exposed to increased circu-
lating concentrations of ET-1 which in turn was associated with
increased coronary vascular resistance and impaired coronary blood
flow. Recently, Theuerle et al.51 have shown that plasma ET-1 is asso-
ciated with invasive CMD in a 32 INOCA patients, however, the rela-
tionship was driven by elevated microvascular resistance and not
impaired CFR.
Limitations
We describe compelling mechanistic evidence for a functional SNP
being linked to CMD. We have followed accepted guidelines for
CMD classifications, but it is recognized there are caveats with any
classification system and acknowledge these are also relevant to this
study. Firstly, we adopted binary cut-offs for the IDP test. It is possible
that indeterminate (grey-zone or borderline) test results may have
misclassified some patients. Furthermore, patients with CMD were
heterogeneous and we aggregated patients with different types of
microvascular dysfunction, e.g. impaired flow reserve, increased
microvascular resistance, abnormal ACh response. Nonetheless, the
vascular phenotype of affected patients was of coronary vascular dys-
function based on consensus guidelines for abnormal coronary
microvascular response during systemic adenosine, an abnormal
vasomotor response to intracoronary ACh, or both.6 In support of
this approach, we observed a strong linear relationship between
CMD and non-invasive ischaemia testing on the exercise treadmill
(Figure 3F). In addition, heterogeneity is the rule rather than excep-
tion when considering many similar cardiovascular disorders, for
example heart failure with preserved ejection fraction.52 Our strati-
fied sensitivity analysis by CMD type, i.e. structural microvascular dis-
ease (i.e. raised IMR) and impaired vasodilator reserve (reduced
CFR) (Table 2), lend further support to the design of our translational
study. Secondly, not all patients underwent treadmill exercise testing.
The tests were indicated as part of standard care and clinical, rather
than core laboratory, reports were available for analysis.
Nevertheless, they were performed according to the Bruce protocol
and the results were determined in a standardized manner, blinded
to rs9349379 allele status. Treadmill exercise testing is an imperfect
measure of ischaemia and hence it is plausible that the known associ-
ation of the rs9349379-G allele with epicardial CAD is a confounding
factor. Gould and Johnson53 recently highlighted how flush ostial
branch vessel occlusion may account for ischaemia despite a visual
‘normal’ angiogram without stenosis. On the other hand, the DTS
has a mature associated literature with proven utility in CMD
patients.54,55 The relatively small sample size and possibility of un-
measured baseline differences increases the possibility of Type I
error. Thirdly, we administered intra-arterial doses of short acting
GTN (100–200lg) to facilitate procedure safety relating to transra-
dial access, coronary arteriography, and invasive coronary vasoreac-
tivity testing. Theoretically, GTN may affect the vascular responses
to ACh; however, the half-life of GTN is around 2 min. Hence, after
10 min, only 3% of the GTN dose is bioavailable and we think the po-
tential for confounding and a false negative test for microvascular
vasospasm is unlikely. Conversely, a positive ACh test confounds as-
sessment of true resting flow and may lead to falsely lowered CFR
and hence we support ACh testing after adenosine assessment.
Finally, we compared the allele prevalence within our cohort from
Scotland with a pooled multicentre contemporary medical genome
reference group of controls. Our study would have been strength-
ened by a control comparator group from the same area and ethnic
background as our subjects. Further, although the SNP did not fulfil
the Hardy–Weinberg equilibrium for the population as a whole, the
control group from this study without CMD was consistent with the
equilibrium (v2 2.99, P= 0.084). It is plausible that HW was not met
in the CMD group due to its association with the rs9349379-G allele
of interest. This study is a cross-sectional analysis of a single genetic
locus and provides associative findings of clinical interest but may
overlook other important genetic risk determinants.
Clinical translation
These observations hypothesis generating particularly given the small
sample size and heterogeneous patient population. The findings re-
quire external validation in other CMD cohorts whilst future work in
populations from different regions would provide helpful context.
Overall, our study supports the case for selective ETA blockade
distinct from ETB modulation in patients with microvascular disease
in the heart. Oral ETA-selective blockade has therapeutic potential by
attenuating the propensity to microvascular vasospasm, increasing
coronary blood flow, and further improving coronary endothelial
function through NO-mediated release.56 Zibotentan is one com-
pound that holds promise as the most ETA selective of all orally active
ETA receptor antagonists, which makes it particularly suited to use in
microvascular angina. A targeted approach using selective ETA recep-
tor antagonist therapy in patients based on genotype is being
assessed in the PRIZE trial (NCT04097314).
12 T.J. Ford et al.
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Conclusion
We identified a genetic risk locus for CMD. The common genetic
polymorphism (SNP rs9349379-G allele) was associated with higher
ET-1 and both invasive CMD and non-invasive tests for ischaemia in
subjects with angina but no obstructive CAD. Mechanistic ex vivo
studies confirmed subjects with this functional allele have preserved
response to ETA receptor blockade. Zibotentan, an orally active ETA
receptor antagonist, reversed an established ET-1-mediated vasocon-
striction. This study offers hope for angina patients although future
trials are needed to determine whether CMD represents a potential
new disease subtype for ETA antagonist therapy.
Supplementary material
Supplementary material is available at European Heart Journal online.
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